Advertisement
Advertisement
Tapimycin

Tapimycin

piperacillin + tazobactam

Manufacturer:

Yung Shin Pharmaceutical

Distributor:

JustRight Healthcare
Concise Prescribing Info
Contents
Piperacillin Na 4 g, tazobactam Na 500 mg
Indications/Uses
Short-term treatment of lower resp tract, intra-abdominal, skin & soft tissue & gynecological infections, UTI (complicated & uncomplicated) & bacterial septicemia.
Dosage/Direction for Use
Administer by IV infusion over 30 min. Adult Usual total daily dose: 3.375 g every 6 hr totaling 13.5 g (piperacillin 12 g/tazobactam 1.5 g). Childn w/ appendicitis &/or peritonitis ≥9 mth, up to 40 kg, & w/ normal renal function Piperacillin 100 mg/tazobactam 12.5 mg/kg every 8 hr. Childn 2-9 mth Piperacillin 80 mg/tazobactam 10 mg/kg every 8 hr. Childn >40 kg & w/ normal renal function Adult dose. All indication Renal impairment CrCl >40 mL/min 3.375 g every 6 hr, 20-40 mL/min 2.25 every 6 hr, <20 mL/min 2.25 g every 8 hr, hemodialysis 2.25 g every 12 hr. An additional dose of 0.75 g should be administered following each dialysis period on hemodialysis days, CAPD 2.25 g every 12 hr.
Contraindications
Hypersensitivity to penicillin. Possible cross-sensitivity w/ other β-lactam antibiotics eg, cephalosporins.
Special Precautions
Serious & occasionally fatal hypersensitivity (anaphylactic/anaphylactoid) reactions (including shock). Severe cutaneous adverse reactions eg, SJS, TEN, DRESS, & acute generalized exanthematous pustulosis. Discontinue use if an allergic reaction or bleeding manifestation occurs; hemophagocytic lymphohistiocytosis is suspected. Nephrotoxicity in critically ill patients. Clostridioides difficile-associated diarrhea. Development of drug resistant bacteria. Patients requiring restricted salt intake. Closely monitor patients who develop skin rash & discontinue use if lesions progress; patients w/ renal impairment or seizure disorders for signs & symptoms of neuromuscular excitability or seizures. Perform periodic assessment of hematopoietic function, especially w/ prolonged therapy ie, ≥21 days; periodic electrolyte determinations in patients w/ low K reserves. Concomitant use w/ vancomycin. Pregnancy & lactation.
Adverse Reactions
Skin reactions, eruptions, increased sweating, erythema multiforme, eczema, maculopapular rash; soft/loose stools, stomatitis, constipation, bloody diarrhea, pseudomembranous colitis; muscular weakness, hallucination, headache, dizziness, fatigue; dry mouth, hypotension; muscle pain, prolonged muscle relaxation; superficial phlebitis; leucopenia, eosinophilia, rarely hemorrhagic manifestations; transient rise in serum levels of ALT, AST, alkaline phosphatase, bilirubin; increased levels of renal function parameters in serum (urea, creatinine), interstitial nephritis; inj site inflammation & pain.
Drug Interactions
May be associated w/ increased incidence of acute kidney injury w/ vancomycin. Substantial inactivation of aminoglycosides. Modest decreases in serum conc of tobramycin. Prolonged t1/2 w/ probenecid. Concomitant use w/ high doses of heparin, oral anticoagulants, or other drugs that may affect blood coagulation system or the thrombocyte function. Prolonged neuromuscular blockade of vecuronium. May reduce clearance of MTX.
MIMS Class
Penicillins
ATC Classification
J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.
Presentation/Packing
Form
Tapimycin powd for inj 4.5 g
Packing/Price
10 × 1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement